Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

• Published in: Nature communications Vol. 16; no. 1; pp. 8236 - 2
• Main Authors: Ninmer, Emily K., Zhu, Hong, Chianese-Bullock, Kimberly A., von Mehren, Margaret, Haas, Naomi B., Ross, Merrick I., Dengel, Lynn T., Slingluff, Craig L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.09.2025; Nature Publishing Group; Nature Portfolio
• Subjects: Addendum; Humanities and Social Sciences; multidisciplinary; Science; Science (multidisciplinary)
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-025-63690-x

[...]we performed a detailed search of the clinical trials data to identify any other complexities that may not have been captured by our original data extraction process. Of the participants with corrected OS data, about half were on arm D (12MP + 6MHP+Cy), resulting in a disproportionate underestimation of OS for that group in the original report. [...]the corrected dataset more strongly supports some of the conclusions regarding the OS benefit after vaccination with melanoma cognate help than in our original report. The corrected dataset still supports the original conclusions regarding RFS, including the favorable benefit from vaccination with melanoma cognate help confined to males (Addendum Figure 2B) with significantly improved RFS in males vaccinated with 12MP + 6MHP compared to 12MP+tet on landmark analysis at end of treatment (1 year) (HR 0.37, 95% CI: 0.17–0.81, P = 0.01, Addendum Figure 2C; original report: HR 0.35, 95% CI: 0.14–0.86, P = 0.02).